The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...